In Utero and Uncertain: Mothers, COVID‑19, and the Autism Question

When we look back at pregnancy during a global pandemic, it feels as though expectant mothers carried not just their own hopes and fears, but also a quiet cloud of uncertainty. In that cloud sits the question of how an infection like COVID‑19 might gently—or not so gently—ripple into the lives of children yet unborn. Recent research suggests there may be more to this story than we first understood.

In one study, researchers examined the health records of over eighteen thousand births during the pandemic and found that among the 4.8 % of children whose mothers had confirmed SARS‑CoV‑2 infection during pregnancy, about 3 % received a diagnosis of a neurodevelopmental disorder by age one—compared with 1.8 % among unexposed infants. After statistical adjustment, male children of infected mothers had nearly double the odds of neurodevelopmental diagnosis compared with unexposed males, though the numbers remain small and the outcomes preliminary. This finding invites deep reflection: an infection that touched the mother might ripple into the earliest years of a child’s life, perhaps in delicate, unseen ways.

Yet a different line of inquiry offers reassurance. A cohort of nearly two thousand children born during the first year of the pandemic, some of whom were exposed to maternal COVID‑19 in utero, showed no increased rate of positive screenings for autism (via the M‑CHAT‑R instrument) between exposed and unexposed groups. Surprisingly, the exposed group had lower positive screening rates though the authors caution the result may stem from reporting differences or selection bias. In short, the data do not uniformly point to a clear risk of autism linked to maternal COVID‑19.

What accounts for the divergent findings? One factor is timing and outcome measurement—one study looked at diagnoses (very early, first year of life) while the other assessed screening positivity (16–30 months). Another is severity of infection, differences in maternal health, socio‑economic context, and the kinds of viral variants involved. A third is that the effect—if real—may be subtle and only emerge over longer follow‑up, beyond infancy and toddlerhood. The authors of the reassuring study explicitly note that longer‐term data are needed. Moreover, neurodevelopment is influenced by myriad prenatal and postnatal factors: maternal health, nutrition, stress, genetics, environment, medical care. Any association with COVID‑19 must be weighed in that broader context.

For mothers and families this means a measured approach. It does not mean a predetermined outcome. It means awareness and open dialogue. If a mother had COVID‑19 during pregnancy, it may be wise to keep developmental monitoring on schedule, engage in enriching early childhood experiences, stay in close partnership with pediatric care providers, and focus on known supportive factors: maternal nutrition, safe sleep practices, early intervention if signs of delay appear. It means not succumbing to fear, but neither dismissing new findings out of hand.

In the landscape of public‑health and developmental science, this is a signal—not a verdict. We are on the cusp of understanding how a pandemic may leave subtle footprints in the earliest chapters of life. The risk is not uniform and remains likely modest, but it underscores the importance of preventive care, vaccination during pregnancy, prenatal monitoring, and postnatal developmental follow‑up. As studies continue to mature, the hope is that clearer guidance will emerge for families and clinicians alike.